Abd El Aziz Mohamed A, McKenna Nicholas P, Jakub James W, Hallemeier Christopher L, Kelley Scott R, Jin Zhaohui, Mathis Kellie L
Division of Colon and Rectal Surgery, Mayo Clinic, Rochester, MN, USA; Department of Internal Medicine, Texas Tech University Health Sciences Center, Paul L. Foster School of Medicine, El Paso, TX, USA.
Department of Surgery, Mayo Clinic, Rochester, MN, USA.
Eur J Surg Oncol. 2022 May;48(5):1100-1103. doi: 10.1016/j.ejso.2021.12.018. Epub 2021 Dec 20.
This study aimed to compare the survival of patients with isolated inguinal lymph node metastases from rectal cancer to patients with inguinal and additional synchronous distant metastases from rectal cancer who treated with curative intent. A retrospective review of all consecutive adult patients with rectal adenocarcinoma and inguinal lymph node involvement who underwent curative therapy at our institution from 2002 to 2020 was conducted. Patients were classified as having synchronous inguinal lymph node metastasis (SILNM), or synchronous inguinal lymph node and distant organ metastasis (SILNDOM). Patients in the SILNM group had a median overall survival of 75 months compared to 17.6 months in the SILNDOM group;p-value = 0.09. The recurrence-free survival for patients with SILNM was 19.6 months compared to 2.4 months in the SILNDOM group;p-value = 0.053. In conclusion, SILNM appears to represent a distinct subgroup of patients with metastatic rectal cancer. These patients warrant consideration of treatment with curative intent. Further studies are needed.
本研究旨在比较直肠癌孤立性腹股沟淋巴结转移患者与接受根治性治疗的直肠癌腹股沟及额外同步远处转移患者的生存率。对2002年至2020年在本机构接受根治性治疗的所有连续性成年直肠腺癌伴腹股沟淋巴结受累患者进行了回顾性研究。患者被分类为有同步腹股沟淋巴结转移(SILNM)或同步腹股沟淋巴结及远处器官转移(SILNDOM)。SILNM组患者的中位总生存期为75个月,而SILNDOM组为17.6个月;p值=0.09。SILNM患者的无复发生存期为19.6个月,而SILNDOM组为2.4个月;p值=0.053。总之,SILNM似乎代表了转移性直肠癌患者的一个独特亚组。这些患者值得考虑进行根治性治疗。还需要进一步的研究。